U.S. Pauses Distribution Of Monoclonal Antibody Treatments That Proved Ineffective Against Omicron Treatments by Regeneron and Eli Lilly have shown disappointing results against the omicron variant, while GlaxoSmithKline’s more effective treatment remains in short supply.